Pim kinase inhibitors: A survey of the patent literature

Expert Opinion on Therapeutic Patents

Volumn 20, Issue 2, 2010, Pages 193-212

  Morwick, Tina ^a  

^a BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

Author keywords

Anti apoptosis; Immunology; Inflammation; Oncology; Pim 1; Pim 2; Pim 3; Proviral insertion site in Moloney murine leukemia virus; Serine threonine kinase

Indexed keywords

ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR; PROTEIN KINASE PIM 1; PROTEIN KINASE PIM 1 INHIBITOR; PYRIMIDINONE DERIVATIVE; UNCLASSIFIED DRUG;

CELL PROLIFERATION; CELL SURVIVAL; CRYSTAL STRUCTURE; DRUG POTENCY; DRUG PROTEIN BINDING; HYDROGEN BOND; IC 50; NONHUMAN; PATENT; REVIEW; STRUCTURE ACTIVITY RELATION;

ANTINEOPLASTIC AGENTS; DRUG DESIGN; HUMANS; NEOPLASMS; PATENTS AS TOPIC; PROTEIN CONFORMATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-PIM-1;

EID: 76149130727     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543770903496442     Document Type: Review

References (98)

1. Fox CJ, Hammerman PS, Cinalli RM, et al. The serine/threonine kinase Pim-2 is a transcriptionally regulated apoptotic inhibitor. Genes Dev 2003;17:1841-1854
2. Saris CJ, Domen J, Berns A. The pim-1 oncogene encodes two related protein-serine/threonine kinases by alternative initiation at AUG and CUG. EMBO J 1991;10: 655-664
3. Cuypers HT, Selten G, Quint W, et al. Murine leukemia virus-induced t-cell lymphomagenesis: integration of proviruses in a distinct chromosomal region. Cell 1984;37:141-150
4. Van Der Lugt NMT, Domen J, Verhoeven E, et al. Proviral tagging in E-myc transgenic mice lacking the Pim-1 proto-oncogene leads to compensatory activation of Pim-2. EMBO J 1995;14:2536-2544
5. Popivanova BK, Li Y-Y, Zheng H, et al. Proto-oncogene, Pim-3 with serine/ threonine kinase activity, is aberrantly expressed in human colon cancer cells and can prevent Bad-mediated apoptosis. Cancer Sci 2007;98:321-328
6. Mikkers H, Nawijn M, Allen J, et al. Mice deficient for all PIM kinases display reduced body size and impaired responses to hematopoietic growth factors. Mol Cell Biol 2004;24:6104-6115
7. Baytel D, Shalom S, Madgar I, et al. The human Pim-2 proto-oncogene and its testicular expression. Biochim Biophys Acta 1998;1442:274-285
8. Domen J, Van Der Lugt N, Laird PW, et al. Analysis of Pim-1 function in mutant mice. Leukemia 1993;7:S108-12
9. Valdman A, Fang X, Pang ST, et al. Pim-1 expression in prostatic intraepithelial neoplasia and human prostate cancer. Prostate 2004;60:367-371
10. Xie Y, Xu K, Dai B, et al. The 44 kDa Pim-1 kinase directly interacts with tyrosine kinase Etk/BMX and protects human prostate cancer cells from apoptosis induced by chemotherapeutic drugs. Oncogene 2006;25:70-78
11. Li Y-Y, Popivanova BK, Nagai Y, et al. Pim-3, a proto-oncogene with serine/ threonine kinase activity, is aberrantly expressed in human pancreatic cancer and phosphorylates Bad to block Bad-mediated apoptosis in human pancreatic cancer cell lines. Cancer Res 2006;66:6741-6747
12. Cohen AM, Grinblat B, Bessler H, et al. Increased expression of the hPim-2 gene in human chronic lymphocytic leukemia and non-Hodgkin lymphoma. Leuk Lymphoma 2004;45:951-955
13. Claudio JO, Masih-Kahn E, Tang H, et al. A molecular compendium of genes expressed in multiple myeloma. Blood 2002;100:2175-2186
14. Qian KC, Wang L, Hickey ER, et al. Structural basis of constitutive activity and a unique nucleotide binding mode of human Pim-1 kinase. J Biol Chem 2005;280:6130-6137
15. Amaravadi R, Thompson CB. The survival kinases Akt and Pim as potential pharmacological targets. J Clin Invest 2005;115:2618-2624
16. Bachmann M, Möröy T. The serine/ threonine kinase Pim-1. Int J Biochem Cell Biol 2005;37:726-730
17. Shirogane G, Fukada T, Muller JMM, et al. Synergistic roles for Pim-1 and c-Myc in STAT3-mediated cell cycle progression and antiapoptosis. Immunity 1999;11:709-719
18. Matikainen S, Sareneva T, Ronni T, et al. Interferon-alpha activates multiple STAT proteins and upregulates proliferation-associated IL-2Ralpha, c-myc, and pim-1 genes in human T cells. Blood 1999;93:1980-1991
19. Laird PW, Van Der Lugt NM, Clarke A, et al. In vivo analysis of Pim-1 deficiency. Nucleic Acids Res 1993;21:4750-4755
20. Yan B, Zemskova M, Holder S, et al. The PIM-2 kinase phosphorylates BAD on serine 112 and reverses BAD-induced cell death. J Biol Chem 2003;278:45358-45367
21. Aho TLT, Sandholm J, Peltola K, et al. Pim-1 kinase promotes inactivation of the pro-apoptotic Bad protein by phosphorylating it on the Ser112 gatekeeper site. FEBS Lett 2004;571:43-49
22. Macdonald A, Campbell DG, Toth R, et al. Pim kinases phosphorylate multiple sites on Bad and promote 14-3-3 binding and dissociation from Bcl-XL. BMC Cell Biology 2006;7:1-14
23. Kelekar A, Chang BS, Harlan JE, et al. Bad is a BH3-containing protein that forms an inactivating dimer with Bcl-xL. Mol Cell Biol 1997;17:740-746
24. Tamburini J, Green AS, Bardet V, et al. Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia. Blood 2009;114:1618-1627
25. White E. The pims and outs of survival signaling: role for the Pim-2 protein kinase in the suppression of apoptosis by cytokines. Genes & Dev 2003;17:1813-1816
26. Faivre S, Kroemer G, Raymond E. Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discovery 2006;5:671-688
27. Adam M, Pogacic V, Bendit M, et al. Targeting PIM kinases impairs survival of hematopoietic cells transformed by kinase inhibitor-sensitive and kinase inhibitor-resistant forms of Fms-like tyrosine kinase 3 and BCR/ABL. Cancer Res 2006;66:3828-3835
28. Hirano T, Ishihara K, Hibi M. Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors. Oncogene 2000;19:2548-2556
29. Bachmann M, Hennemann H, Xing PX, et al. The ongogenic serine/threonine kinase Pim-1 phosphorylates and inhibits the activity of Cdc25C-associated Kinase 1 (C-TAK1). J Biol Chem 2004;279:48319-48328
30. Boehringer Ingelheim International GMBH. Methods and compounds for the diagnosis of inflammatory disease and identification of pharmacological agents useful in the treatment of inflammatory disease. US0125231; 2003
31. Yang J, Li X, Hanidu A, et al. PIM2 is required for interleukin-6 expression induced by IL-1, TNFalpha and LPS. Available from: http://www.fasebj.org/cgi/ content/meeting-abstract/22/ 2-MeetingAbstracts/426. [Last accessed 9 September 2009]
32. Fox J, Hammerman PS, Thompson CB. The Pim kinases control rapamycin-resistant T cell survival and activation. J Exp Med 2005;201:259-266
33. Vertex Pharmaceuticals, Inc. Compositions useful as inhibitors of protein kinases. WO2004058769; 2004
34. Vertex Pharmaceuticals, Inc. Compositions useful as inhibitors of protein kinases. US7268136; 2007
35. Grey R, Pierce AC, Bemis GW, et al. Structure-based design of 3-aryl-6-amino-triazolo[4,3-b]pyridazine inhibitors of Pim-1 kinase. Bioorg Med Chem Lett 2009;19:3019-3022
36. SuperGen, Inc. Imidazo[1,2B]pyridazine and pyrazolo[1,5-A]pyrimidine derivatives and their use as protein kinase inhibitors. WO2008058126; 2008
37. SGI-1776 is an inhibitor of PIM kinases, a family of oncoproteins that promote tumor cell survival. SuperGen Pipeline. Available from: http://www.supergen.com/ whatwedo/product.html?productId=2. [Last accessed 2 September 2009]
38. Fabian MA, Biffs WH, Treiber DK, et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nature Biotech 2005;23:329-336
39. Fedorov O, Marsden B, Pogacic V, et al. A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci USA 2007;104:20523-20528
40. Bullock AN, Debreczeni JE, Fedorov OY, et al. Structural basis of inhibitor specificity of the human protooncogene proviral insertion site in moloney murine leukemia virus (PIM-1) kinase. J Med Chem 2005;48:7604-7614
41. Pogacic V, Bullock AN, Fedorov O, et al. Structural analysis identifies imidazo [1,2-b]pyridazines as PIM kinase inhibitors with in vitro antileukemic activity. Cancer Res 2007;67:6916-6924
42. Centro Nacional De Investigaciones Oncologicas (CNIO) Imidazopyridazines for use as protein kinase inhibitors. WO2009060197; 2009
43. Centro Nacional De Investigaciones Oncologicas (CNIO) Imidazolothiadiazoles for use as protein kinase inhibitors. WO2009040552; 2009
44. Exelixis, Inc. 6-Phenylpyrimidinones as Pim modulators. WO2008133955; 2008
45. Exelixis, Inc. Benzofuropyrimidinones as protein kinase inhibitors. WO2009086264; 2009
46. Abbott Laboratories. Pim kinase inhibitors as cancer chemotherapeutics. WO2008082839; 2008
47. Tao Z-F, Hasvold L, Leverson JD, et al. Discovery of 3H-Benzo[4,5] thieno[3,2-d] pyrimidine-4-ones as potent, highly selective, and orally bioavailable inhibitors of the human protooncogene proviral insertion site in moloney murine leukemia virus (PIM) kinases. J Med Chem 2009;52:6621-6636
48. Abbott Laboratories. Pim kinase inhibitors as cancer chemotherapeutics. WO2008082840; 2008
49. ExElixis, Inc. Pyridopyrimidinone inhibitors of Pim-1 and/or Pim-3. WO2007044724; 2007
50. Myznikov LV, Hrabalek A, Koldobskii GI. Drugs in the tetrazole series, (review). Chem Heterocycl Compd 2007;43:1-9
51. Boehringer Ingelheim International GMBH. Pim kinase inhibitors and methods of their use. WO2008022164; 2008
52. Qian K, Wang L, Cywin CL, et al. Hit to lead account of the discovery of a new class of inhibitors of Pim kinases and crystallographic studies revealing an unusual kinase binding mode. J Med Chem 2009;52:1814-1827
53. MUSC foundation for research development. Inhibitors of Pim protein kinases, compositions, and methods for treating cancer. WO2009064486; 2009
54. Xia Z, Knaak C, Ma J, et al. Synthesis and evaluation of novel inhibitors of Pim-1 and Pim-2 protein kinases. J Med Chem 2009;52:74-86
55. Henke BR, Blanchard SG, Brackeen MF, et al. N-(2-Benzoylphenyl)-L- tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents. J Med Chem 1998;41:5020-5036
56. Buckle DR, Cantello BCC, Cawthorne MA, et al. Nonthiazolidinedione antihyperglycemic agents. 1: alpha-heteroatom substituted beta-phenylpropanoic acids. Bioorg Med Chem Lett 1996;6:2121-2126
57. Novartis Vaccines and Diagnostics, Inc. Pim kinase inhibitors and methods of their use. WO2008106692; 2008
58. Oncorex, Inc. Novel hydroxyindole derivatives. WO2008056634; 2008
59. Oncorex, KK. Pim-1 inhibitors. JP200784494; 2007
60. Bridges AJ. Chemical inhibitors of protein kinases. Chem Rev 2001;101:2541-2571
61. Holder S, Lilly M, Brown ML. Comparative molecular field analysis of flavonoid inhibitors of the PIM-1 kinase. Biorg Med Chem 2007;15:6463-6473
62. Holder S, Zemskova M, Zhang C, et al. Characterization of a potent and selective small-molecule inhibitor of the PIM1 kinase. Mol Cancer Ther 2007;6:163-172
63. Vertex Pharmaceuticals, Inc. Benzisoxazole derivatives useful as inhibitors of protein kinases. WO2004058749; 2004
64. Vertex Pharmaceuticals, Inc. Compositions useful as inhibitors of protein kinases. US7226919; 2007
65. Schering Corp. Pyrazolopyrimidines as protein kinase inhibitors. WO2007041712; 2007
66. Schering Corp. Pyrazolopyrimidines as protein kinase inhibitors. WO2007044407; 2007
67. Schering Corp. Methods for inhibiting protein kinases. WO2007056468; 2007
68. Schering Corp. Imidazopyrazines as protein kinase inhibitors. WO2007145921; 2007
69. Array Biopharma, Inc. Imidazo[1,2-A] pyridine compounds as receptor tyrosine kinase inhibitors. WO2008121687; 2008
70. Array Biopharma, Inc. Imidazo[1,2-A] pyridine compounds as receptor tyrosine kinase inhibitors. WO2008124323; 2008
71. Genentech, Inc. 2-Amido-4-isoxazolyl thiazole compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof. WO2008022002; 2008
72. Buijsman, R. Structural aspects of kinases and their inhibitors. In: Kubinyi H, Müller G, editors, Chemogenomics in drug discovery. Wiley-VCH Verlag GmbH & Co.; 2004. p. 191-217
73. Jacobs MD, Black J, Futer O, et al. Pim-1 ligand-bound structures reveal the mechanism of serine/threonine kinase inhibition by LY294002. J Biol Chem 2005;280:13728-13734
74. Available from: http://www.rcsb.org/ pdb/home/home.do. [Last accessed 2 September 2009]
75. Pierce AC, Jacobs M, Stuver-Moody C. Docking study yields four novel inhibitors of the protooncogene Pim-1 kinase. J Med Chem 2008;51:1972-1975
76. Pierce AC, Sandretto KL, Bemis, GW. Kinase inhibitors and the case for CHO hydrogen bonds in protein-ligand binding. Proteins Struct Funct Genet 2002;49:567-576
77. Cheney IW, Yan S, Appleby T, et al. Identification and structure-activity relationships of substituted pyridones as inhibitors of Pim-1 kinase. Biorg Med Chem Lett 2007;17:1679-1683
78. Shafer CM, Lindvall M, Bellamacina C, et al. 4-(1H-Indazol-5-yl)-6- phenylpyrimidin-2 (1H)-one analogs as potent CDC7 inhibitors. Bioorg Med Chem Lett 2008;18:4482-4485
79. Vertex Pharmaceuticals. Crystal structures of human pim-1 complexes with ligands and their binding sites and applications in drug screening and design. WO2004090106; 2004
80. Plexxikon. Crystal structure of human PIM-1 kinase and complexes with AMP-PNP and use in drug screening and design. WO2004024895; 2004
81. Qian KC, Studts J, Wang L, et al. Expression, purification, crystallization and preliminary crystallographic analysis of human Pim-1 kinase. Acta Crystallogr Sect F Struct Biol Cryst Commun 2005;61:96-99
82. Debreczeni JE, Bullock AN, Atilla GE, et al. Ruthenium half-sandwich complexes bound to protein kinase Pim-1. Angew Chem Int Ed Engl 2006;45:1580-1585
83. Kumar A, Mandiyan V, Suzuki Y, et al. Crystal structures of proto-oncogene kinase Pim1: a target of aberrant somatic hypermutations in diffuse large cell lymphoma. J Mol Biol 2005;348:183-193
84. Manning G, Whyte DB, Martinez R, et al. The protein kinase complement of the human genome. Science 2002;298:1912-1934
85. Cohen P. The regulation of protein function by multisite phosphorylation-a 25 year update. Trends Biochem Sci 2000;25:596-601
86. Jänne PA, Gray N, Settleman J. Factors underlying sensitivity of cancers to small-molecule kinase inhibitors. Nat Rev Drug Discov 2009;8:709-723
87. Bikker JA, Brooijmans N, Wissner A, et al. Kinase domain mutations in cancer: implications for small molecule drug design strategies. J Med Chem 2009;52:1493-1509
88. Zhang J, Yang PL, Gray NS. Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer 2009;9:28-39
89. Gaestel M, Kotlyarov A, Kracht M. Targeting innate immunity protein kinase signalling in inflammation. Nat Rev Drug Discovery 2009;8:480-499
90. Khosrow K. Anti-inflammatory agents as cancer therapeutics. Adv Pharmacol 2009;57:31-89
91. Rini B, Kar S, Kirkpatrick P. Temsirolimus. Nat Rev Drug Discov 2007;6:599
92. Atkins MB, Yasothan U, Kirkpatrick P. Everolimus. Nat Rev Drug Discov 2009;8:535
93. Pagano MA, Bain J, Kazimierczuk Z, et al. The selectivity of inhibitors of protein kinase CK2: an update. Biochem J 2008;415:353-365
94. Davies SP, Reddy H, Caivano M, et al. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 2000;351:95-105
95. Ahmed K, Gerber DA, Cochet C. Joining the cell survival squad: an emerging role for protein kinase CK2. Trends Cell Biol 2002;12:226-230
96. Guerra B, Issinger O-G. Protein kinase CK2 and its role in cellular proliferation, development and pathology. Electrophoresis 1999;20:391-408
97. Hennessy BT, Smith DL, Ram PT, et al. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 2005;4:988-1004
98. Pan Q, Bao LW, Kleer CG, et al. Protein kinase Ce is a predictive biomarker of aggressive breast cancer and a validated target for RNA interference anticancer therapy. Cancer Res 2005;65:8366-8371